With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...

AstraZeneca PLC through Alexion, AstraZeneca Rare DiseasesUltomiris(ravulizumab) was approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

The FDA has approved Ultomiris to reduce proteinuria in adult patients with primary immunoglobulin A, or IgA, nephropathy who ...

AstraZeneca Plc was always going to do another deal one day, but few followers of the UK drugmaker expected this: It’s splashing out $39 billion in cash and stock for US rare-disease specialist ...

Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the U.S. to reduce proteinuria in adults ...

“We had three very unique patients—three different walks of life, three different communities, from various states—yet their journey led them all to a very common place,” Tamar Thompson, Alexion's ...

An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...